Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) Return on Sales (2021 - 2025)

Verrica Pharmaceuticals has reported Return on Sales over the past 5 years, most recently at 1.63% for Q4 2025.

  • Quarterly results put Return on Sales at 1.63% for Q4 2025, up 3777.0% from a year ago — trailing twelve months through Dec 2025 was 0.53% (up 611.0% YoY), and the annual figure for FY2025 was 0.53%, up 924.0%.
  • Return on Sales for Q4 2025 was 1.63% at Verrica Pharmaceuticals, down from 0.02% in the prior quarter.
  • Over the last five years, Return on Sales for VRCA hit a ceiling of 0.18% in Q3 2022 and a floor of 178.08% in Q1 2023.
  • Median Return on Sales over the past 5 years was 6.9% (2023), compared with a mean of 26.77%.
  • Biggest five-year swings in Return on Sales: crashed -15843bps in 2023 and later soared 17277bps in 2024.
  • Verrica Pharmaceuticals' Return on Sales stood at 2.92% in 2021, then tumbled by -2881bps to 87.13% in 2022, then surged by 86bps to 12.4% in 2023, then plummeted by -218bps to 39.4% in 2024, then soared by 96bps to 1.63% in 2025.
  • The last three reported values for Return on Sales were 1.63% (Q4 2025), 0.02% (Q3 2025), and 0.03% (Q2 2025) per Business Quant data.